Phosphatidylserine Improves Cognitive Function in the Elderly

Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Jun 8, 2021

Keywords

ClinConnect Summary

This is a randomized, controlled, double-blind clinical trial, in which 100 subjects were randomly assigned to the treatment group and the control group 1:1 by computer generated random numbers. Before start of the study, all the subjects underwent the first magnetic resonance (MR) and electroencephalogram (EEG) data collection. The working memory capacity of subjects in the N-back paradigm was measured (collected during the N-back task in the EEG test), and the cognition was measured by MOCA and MMSE. After the first data collection was completed, subjects in the treatment group oral the P...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Age 60 to 70, gender is not limited.
• Exclusion Criteria:
• • Delirium, confusion, confusion of consciousness.
• • Alzheimer's disease, Parkinson's disease, stroke, cerebral hemorrhage, brain tumor, hydrocephalus.
• • Viral, fungal, and syphilis infections.
• • Sufferers from cerebrovascular disease (as demonstrated by a Hachinski ischemic score, or neuroimaging test).
• • Repeated mild head trauma, or head trauma resulting in loss of consciousness (more than 1h).
• • Depression, mania, and other mental disorders.
• • Alcoholism and drug dependence.
• * The following diseases may lead to mental retardation:
• • Kidney disease, respiratory system disease, heart disease, liver disease, uncontrolled diabetes, endocrine, metabolic, blood disease, malignant disease, more than 2 years have not been relieved.
• • Taken any medication that may cause psychosis or affect intelligence in the past 1 month.
• • known allergy to phosphatidylserine or related ingredients.